每周股票复盘：开立医疗（300633）取消监事会并修订章程

Core Viewpoint - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., has undergone significant governance changes, including the cancellation of its supervisory board and amendments to its articles of association, which were approved during its recent shareholder meeting [2][4]. Group 1: Stock Performance - As of December 31, 2025, the stock price of Kaili Medical closed at 26.42 yuan, down 0.49% from the previous week [1]. - The stock reached a high of 26.59 yuan and a low of 25.92 yuan during the week [1]. - The company's current total market capitalization is 11.432 billion yuan, ranking 26th out of 127 in the medical device sector and 1709th out of 5181 in the A-share market [1]. Group 2: Corporate Governance Changes - The second extraordinary general meeting of shareholders was held on December 30, 2025, where the cancellation of the supervisory board and amendments to the company's governance structure were approved [2][4]. - The meeting was deemed legal and effective, with 55.3717% of the total voting rights represented by attending shareholders [2][4]. - The proposals to cancel the supervisory board and amend the articles of association received over two-thirds approval, while other proposals received a majority [2]. Group 3: Employee Representation - The company held a representative assembly on December 30, 2025, electing Feng Naizhang as the employee representative director for the fourth board of directors [3]. - Feng Naizhang, previously a non-employee representative director, meets the qualifications set forth in the Company Law and the company's articles of association [3]. - The composition of the board and its specialized committees remains unchanged, with the number of concurrent executives and employee representative directors not exceeding half of the total board members [3].